Plasma Sample Clauses
The 'Plasma' clause defines the rights and obligations of parties regarding the use, handling, or transfer of plasma, which may refer to a physical substance (such as blood plasma) or a specific technology or product named 'Plasma.' In practice, this clause typically outlines standards for quality, safety, and compliance with applicable regulations, and may specify procedures for delivery, storage, or liability in case of contamination or defects. Its core function is to ensure that all parties clearly understand their responsibilities and the standards required when dealing with plasma, thereby minimizing risks and potential disputes related to its use or transfer.
Plasma. Proteins
Plasma wall studies, exploring plasma-wall interaction scenarios with Li coating and Li-liquid limiter concepts.
Plasma wall interaction and divertor physics;
Plasma. (a) Cerus and BHC acknowledge and agree that the Cooperative Development Work, as defined in the RBC/FFP Agreement, for the Plasma System;
(i) continues with respect to activities directed toward obtaining CE ▇▇▇▇ in the European Territory;
(ii) is terminated, effective January 1, 2005, with respect to activities directed to North America;
(b) With respect to activities directed toward obtaining CE ▇▇▇▇ for the Plasma System and related manufacturing and validation, Baxter agrees, at Cerus’ request and expense, to carry out the further development activities set forth on Exhibit C to this Agreement within the time schedules set forth on such Exhibit for such activities. The charge for such activities will not exceed the amount set forth on such Exhibit, provided that the scope of such activities is not expanded. Cerus agrees to fund those Baxter activities, as well as Cerus activities, directed toward completing the application for CE ▇▇▇▇, including through funding from the Escrow Account pursuant to Section 2.8, above.
(c) With respect to the countries of the BioOne Territory, it is acknowledged that Cerus has been discussing with BioOne and Baxter a potential transaction related to the Plasma System that is similar to the transaction previously EXECUTION 10 RESTRUCTURING AND SETTLEMENT AGREEMENT [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. entered into for the Platelet System. In the event such a transaction is entered into, it is anticipated that development and commercialization will be carried on by BioOne. Pending the completion of the transactions, the Parties do not expect that any Cooperative Development work will be funded specifically directed to the countries of the BioOne Territory. The parties agree to cooperate to supply information to BioOne and engage in discussions with BioOne to facilitate the completion of such transaction. Such activities will not be considered Cooperative Development work that is subject to funding under the RBC/FFP Agreement. In the event that such transaction is not entered into with BioOne or another entity within [ * ] months of the date of this Agreement, the Cooperative Development Work for the Plasma System will be considered terminated with respect to the countries of the BioOne Territory.
(d) With respect to ac...
Plasma. Therm shall sell and Distributor shall purchase the Products at a price that equals 85% of Plasma- Therm's U.S. list price and spare parts at a price that equals 70% of Plasma-Therm's U.S. list price. Special pricing on large blanket orders will be considered. Therefore, the Distributor may set its price according to what the market will bare; however, the Distributor's pricing should not become excessive. If the Distributor requests additional discounts from Plasma- Therm, greater than 85% of Plasma-Therm's U.S. list price for the Products and greater than 70% of Plasma-Therm's U.S. list price for spare parts, the Distributor will provide selling and cost price information to Plasma-Therm so that both parties may cooperate to meet the customer's budget. Any changes in the list price for such Products shall be determined solely by, and are subject to the exclusive discretion of, Plasma-Therm. Distributor shall be promptly notified in writing ninety (90) days prior to any price changes. The cost of any discounts on the Products that distributor provides to its customers shall be borne solely by Distributor. Plasma-Therm, acting in its sole discretion, shall have the right to reject any non-standard order from Distributor. Plasma-Therm will consider special changes on systems, provided they are submitted for approval at the quotation stage. The terms of all sales by Plasma-Therm to Distributor shall be ex-works. Plasma-Therm's factory charges for all crating, handling, shipping costs, insurance, demurrage, import duties and other taxes or the like to be paid by Distributor. Risk of loss or damage of Products shall shift to Distributor upon Plasma-Therm's delivery of Products to the carrier. The terms of payment shall be net thirty (30) days from shipment date with all payments to be made by wire transfer; Title of equipment will pass to Distributor at ex-works point. If Distributor fails to comply with the terms of this paragraph 3 within thirty (30) days following written notice from Plasma-Therm of Distributor's failure to comply, this Agreement shall terminate immediately upon written notice from Plasma-Therm of such termination and all obligations due Plasma-Therm shall become immediately due.
Plasma. Under the RBC/FFP Agreement, as to the field of inactivation of pathogens in plasma components of blood: all licenses and related rights in North America; EXECUTION 11 RESTRUCTURING AND SETTLEMENT AGREEMENT [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Plasma. Artificial Limbs and eyes; Casts; Splints; Braces and Rentalof its administration -Vision Care: effective November during and month period. UnlimitedLenses. Contact lenses if medically required (no sun glasses). HospitalRoom Rate -Coverage outside Canada for Doctorsand Hospitalwithin fee schedule -Hearing Aids (6)
Plasma accelerating structures, as they shall be further developed in this work, define the frontier in high gradient acceleration and therefore address this important challenge. The May 2014 Particle Physics Project Prioritization Panel (P5) report on “Building for Discovery – Strategic Plan for U.S. Particle Physics in the Global Context” identifies the “critical need for technical breakthroughs that will yield more cost-effective accelerators. For example, ultra-high gradient accelerator techniques will require the development of power sources …, and accelerating structures (plasmas, metallic, and dielectric) that can sustain high average power, have high damage threshold, and can be cascaded.” As introduced above, proof-of-principle measurements for GeV-class plasma acceleration have been published in high-ranking journals and the physics principles are proven. The science communities have assessed plasma acceleration and have confirmed its potential, as seen in the quotes above. Issues and problems are known, are predominantly of technical nature and requirements for improvements have been listed. The EuroNNAc2 network pursues the approach that user beam quality for plasma accelerators can be achieved with adequate resources and a combined effort from experts in different laboratories with a large range of expert competences. No fundamental issue that prevents these objectives is known today. It can be seen from Figure 1 that there are many institutes in Europe involved in advanced accelerator research and that there are 16 major research facilities operating or under construction in Europe. A coordinated strategy is required for creating a “combined effort” as mentioned above. The AWAKE experiment is developing proton beams as new and hopefully highly efficient power sources for plasma accelerators. The high stored power in a single proton bunch should allow driving electrons with a single or few acceleration stages to high beam energy. This is required for a particle physics collider. The EuPRAXIA project aims at using the available power source technology of modern lasers as of today and will not address limitations in the power source, except stability. We appreciate that laser efficiency and repetition rate are important issues for high power applications like plasma linear colliders, requiring R&D and significant improvements. There are several Horizon 2020 proposals for the Future Emerging Technology (FET) program on the subject of innovative laser po...
Plasma accelerators presently offer lower beam energy than conventional accelerators. This is mainly due to the fact that cascading of plasma structures has so far not been a priority and has only recently been achieved for the first time.
Plasma. Therm and BDM each agree to keep in confidence and prevent any disclosure of the Confidential Information, to any person or persons outside their respective organizations or any unauthorized person or persons within such organizations, with the exception of subcontractors to either party who agree in writing to be bound by these obligations of confidentiality, for a period of three (3) years from termination of this Contract. Confidential Information shall not include information which: